Influenza and respiratory syncytial virus in the elderly

References

• Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine17(Suppl. 1), S3–S10 (1999).
   PubMed Web of Science ®Google Scholar
• Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science305(5682), 371–376 (2004).
   PubMed Web of Science ®Google Scholar
• Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev.56(1), 152–179 (1992).
   PubMedGoogle Scholar
• Taubenberger JK, Reid AH, Lourens RM et al. Characterization of the 1918 influenza virus polymerase genes. Nature437(7060), 889–893 (2005).
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Lochindarat S, Srisan P et al. Cases of influenza A (H5N1) – Thailand, 2004. MMWR Morb. Mortal. Wkly Rep.53, 100–103 (2004).
   PubMedGoogle Scholar
• Tran TH, Nguyen TL, Nguyen TD et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med.350(12), 1179–1188 (2004).
   PubMed Web of Science ®Google Scholar
• Webster RG, Govorkova EA. H5N1 influenza – continuing evolution and spread. N. Engl. J. Med.355(21), 2174–2177 (2006).
   PubMed Web of Science ®Google Scholar
• Webby RJ, Webster RG. Are we ready for pandemic influenza? Science302(5650), 1519–1522 (2003).
   PubMed Web of Science ®Google Scholar
• Fouchier RA, Schneeberger PM, Rozendaal FW et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl Acad. Sci. USA101(5), 1356–1361 (2004).
   PubMed Web of Science ®Google Scholar
• Peiris M, Yuen KY, Leung CW et al. Human infection with influenza H9N2. Lancet354(9182), 916–917 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson KG. Human influenza. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Sciences, Oxford, UK219–264 (1998).
   Google Scholar
• Fleming DM, Elliot AJ, Cross KW. Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiol. Infect.135(7), 1099–1108 (2007).
   PubMed Web of Science ®Google Scholar
• de Jong MD, Bach VC, Phan TQ et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med.352(7), 686–691 (2005).
   PubMed Web of Science ®Google Scholar
• Brady MT, Sears SD, Pacini DL et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob. Agents Chemother.34(9), 1633–1636 (1990).
   PubMed Web of Science ®Google Scholar
• Dolin R, Reichman RC, Madore HP et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med.307(10), 580–584 (1982).
   PubMed Web of Science ®Google Scholar
• Hall CB, Dolin R, Gala CL et al. Children with influenza A infection: treatment with rimantadine. Pediatrics80(2), 275–282 (1987).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob. Agents Chemother.29(2), 339–341 (1986).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sperber SJ, Belshe RB et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother.35(9), 1741–1747 (1991).
   PubMed Web of Science ®Google Scholar
• Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J.4(11), 3021–3024 (1985).
   PubMed Web of Science ®Google Scholar
• Monto AS. The role of antivirals in the control of influenza. Vaccine21(16), 1796–1800 (2003).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Belshe RB, Clover RD et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med.321(25), 1696–1702 (1989).
   PubMed Web of Science ®Google Scholar
• Mast EE, Harmon MW, Gravenstein S et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol.134(9), 988–997 (1991).
   PubMed Web of Science ®Google Scholar
• Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis.180(4), 935–939 (1999).
   PubMed Web of Science ®Google Scholar
• Barr IG, Hurt AC, Deed N et al. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res.75(2), 173–176 (2007).
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet366(9492), 1175–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Saito R, Li D, Suzuki Y et al. High prevalence of amantadine-resistance influenza A (H3N2) in six prefectures, Japan, in the 2005–2006 season. J. Med. Virol.79(10), 1569–1576 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis.193(12), 1626–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res.70(3), 121–131 (2006).
   PubMed Web of Science ®Google Scholar
• Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine–oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther.12(3), 363–370 (2007).
   PubMed Web of Science ®Google Scholar
• Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother.51(1), 123–129 (2003).
   PubMed Web of Science ®Google Scholar
• Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J. Infect. Dis.180(2), 254–261 (1999).
   PubMed Web of Science ®Google Scholar
• Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother.44(Suppl. B), 23–29 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.Lancet355(9218), 1845–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA283(8), 1016–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis.11(2), 201–209 (2005).
   PubMed Web of Science ®Google Scholar
• The Writing Committee of the WHO Consultation on Human Influenza. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med.353, 1374–1385 (2005).
   Google Scholar
• Govorkova EA, Ilyushina NA, Boltz DA et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother.51(4), 1414–1424 (2007).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother.45(10), 2723–2732 (2001).
   PubMed Web of Science ®Google Scholar
• Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res.48(2), 101–115 (2000).
   PubMed Web of Science ®Google Scholar
• Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother.55(Suppl. 1), i5–i21 (2005).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J.20(2), 127–133 (2001).
   PubMed Web of Science ®Google Scholar
• de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med.353(25), 2667–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature437(7062), 1108 (2005).
   PubMed Web of Science ®Google Scholar
• Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill.13(5) (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Department of Health. CMO’s Update: Major Changes to the Policy on Influenza Immunisation. UK Department of Health, (2000).
   Google Scholar
• Donaldson L, Beasley C, Ridge K. The Influenza Immunisation Programme 2007/2008. UK Department of Health, London, UK (2007).
   Google Scholar
• Joseph C, Goddard N, Gelb D. Influenza vaccine uptake and distribution in England and Wales using data from the General Practice Research Database, 1989/90–2003/04. J. Public Health27(4), 371–377 (2005).
   Google Scholar
• Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.3, CD004876 (2006).
   PubMedGoogle Scholar
• Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272(21), 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Kang I, Hong MS, Nolasco H et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J. Immunol.173(1), 673–681 (2004).
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine23(Suppl. 1), S10–S25 (2005).
   PubMed Web of Science ®Google Scholar
• Jefferson T. Influenza vaccination: policy versus evidence. Br. Med. J.333(7574), 912–915 (2006).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet366(9492), 1165–1174 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan RE, Hawker JI, Ayres JG et al. A case–control study of elderly patients with acute respiratory illness: effect of influenza vaccination on admission to hospital in winter 2003–2004. Vaccine25(46), 7909–7913 (2007).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect.Dis.7(10), 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Mufson MA, Levine HD, Wasil RE, Mocega-Gonzalez HE, Krause HE. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am. J. Epidemiol.98(2), 88–95 (1973).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, McNally T, Silverman M et al. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine24(1), 102–108 (2006).
   PubMed Web of Science ®Google Scholar
• Parrott RH, Kim HW, Arrobio JO et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol.98(4), 289–300 (1973).
   PubMed Web of Science ®Google Scholar
• Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr. Infect. Dis. J.22(9), 823–827 (2003).
   PubMed Web of Science ®Google Scholar
• The Impact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics102(3), 531–537 (1998).
   Google Scholar
• Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet358(9291), 1410–1416 (2001).
   PubMed Web of Science ®Google Scholar
• Ross AM, Kai J, Salter R, Ross J, Fleming DM. Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors. Commun. Dis. Public Health3(4), 256–260 (2000).
   PubMedGoogle Scholar
• Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J. Infect. Dis.195(7), 1046–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis.189(2), 233–238 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming DM, Elliot AJ, Nguyen-van Tam JS, Watson JM, Wise R. A Winter’s Tale: Coming to Terms with Winter Respiratory Illnesses. Health Protection Agency, London, UK (2005).
   Google Scholar
• Goddard NL, Kyncl J, Watson JM. Appropriateness of thresholds currently used to describe influenza activity in England. Commun. Dis. Public Health6(3), 238–245 (2003).
   PubMedGoogle Scholar
• Salisbury DM. Influenza Season 2005/06 – Use of Oseltamivir. Department of Health, London, UK (2006).
   Google Scholar
• Fleming DM, Elliot AJ. Changing disease incidence: the consulting room perspective. Br. J. Gen. Pract.56(532), 820–824 (2006).
   PubMed Web of Science ®Google Scholar
• Standing Medical Advisory Committee Subcommittee on Antibiotic Resistance. In: The Path of Least Resistance. Hart M, Livermoore DM, Weinberg JR (Eds). Department of Health, London, 1–152 (1998).
   Google Scholar
• Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog.3(10), 1470–1476 (2007).
   PubMed Web of Science ®Google Scholar
• Elliot AJ, Fleming DM. Surveillance of influenza-like illness in England and Wales during 1966–2006. Euro Surveill.11(10), 249–250 (2006).
   PubMedGoogle Scholar
• Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun. Dis. Public Health3(1), 32–38 (2000).
   PubMedGoogle Scholar
• Elliot AJ, Cross KW, Fleming DM. Acute respiratory infections and winter pressures on hospital admissions in England and Wales 1990–2005. J. Public Health30(1), 91–98 (2008).
   Google Scholar
• Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J. Infect. Dis.181(3), 831–837 (2000).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Mangtani P, Hajat S, Kovats S, Wilkinson P, Armstrong B. The association of respiratory syncytial virus infection and influenza with emergency admissions for respiratory disease in London: an analysis of routine surveillance data. Clin. Infect. Dis.42(5), 640–646 (2006).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352(17), 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Cunningham CK, Barker WH et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis.172(2), 389–394 (1995).
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine25(5), 846–855 (2007).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med.331(12), 778–784 (1994).
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine20(13–14), 1831–1836 (2002).
   PubMed Web of Science ®Google Scholar
• Monto AS, Comanor L, Shay DK, Thompson WW. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. J. Infect. Dis.194(Suppl. 2), S92–S97 (2006).
   Web of Science ®Google Scholar
• Department of Health. UK Health Department’s Influenza Pandemic Contingency Plan. Department of Health, London, UK (2005).
   Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiol. Infect.133(2), 255–262 (2005).
   PubMed Web of Science ®Google Scholar
• Elliot AJ, Cross KW, Smith GE, Fleming DM. Do children drive the spread of influenza-like illness in the community? Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17–23 June 2007.
   Google Scholar
• Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med.357(14), 1373–1381 (2007).
   PubMed Web of Science ®Google Scholar
• Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vaccination on major cause-specific mortality. Vaccine25(7), 1196–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur. Respir. J.23(3), 363–368 (2004).
   PubMed Web of Science ®Google Scholar
• Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet357(9261), 1008–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Ortqvist A, Granath F, Askling J, Hedlund J. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur. Respir. J.30(3), 414–422 (2007).
   PubMed Web of Science ®Google Scholar
• Rizzo C, Viboud C, Montomoli E, Simonsen L, Miller MA. Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage. Vaccine24(42–43), 6468–6475 (2006).
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cumberland P, Hodgson CR et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J. Infect. Dis.190(1), 1–10 (2004).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Reichert TA, Viboud C et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch. Intern. Med.165(3), 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Paget WJ, Meerhoff TJ, Meijer A. Epidemiological and virological assessment of influenza activity in Europe during the 2003–2004 season. Euro Surveill.10(4), 107–111 (2005).
   PubMedGoogle Scholar
• Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine20(Suppl. 1), S27–S31 (2001).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine25(42), 7372–7378 (2007).
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine19(25–26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17(23–24), 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17(2), 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• de Bruijn I, Meyer I, Gerez L et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine26(1), 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection32(4), 191–198 (2004).
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine21(11–12), 1268–1274 (2003).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007 MMWR Recommended Report.56(RR-6), 1–54 (2007).
   PubMedGoogle Scholar
• Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine16(18), 1756–1760 (1998).
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Arden NH, Grigorieva E et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine19(2–3), 308–318 (2000).
   PubMed Web of Science ®Google Scholar